evo视讯官网

专注给予质高价优

科学论文

A randomized phase 1 study evaluating the pharmacokinetic equivalence of proposed biosimilar HLX14 and denosumab in healthy Chinese volunteers
ASCPT 2022
A Phase 1 study comparing the pharmacokinetics, safety and immunogenicity between HLX12, a proposed ramucirumab biosimilar, with reference ramucirumab in healthy Chinese males
ASCPT 2022
A phase 1 study evaluating the bioequivalence between HLX11, a China-manufactured pertuzumab biosimilar candidate, and pertuzumab from three different sources in healthy Chinese male subjects
ASCPT 2022
A phase 1 study of serplulimab (a novel anti-PD-1 antibody) in combination with HLX04 (an anti-VEGF antibody) in patients with advanced solid tumors
ASCPT 2022
A randomized phase 1 study to compare the pharmacokinetics, safety, tolerability and immunogenicity between HLX02, reference US- and EU-approved trastuzumab in healthy Chinese male volunteers
ASCPT 2022
A Phase 2 study of serplulimab plus HLX07 in patients with advanced head and neck tumours
ICHNO–ECHNO 2022

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97